ATE516503T1 - Auswahl von kopf-hals-krebspatienten für eine behandlung mit arzneimitteln zur anzielung des egfr-pfades - Google Patents

Auswahl von kopf-hals-krebspatienten für eine behandlung mit arzneimitteln zur anzielung des egfr-pfades

Info

Publication number
ATE516503T1
ATE516503T1 AT09774994T AT09774994T ATE516503T1 AT E516503 T1 ATE516503 T1 AT E516503T1 AT 09774994 T AT09774994 T AT 09774994T AT 09774994 T AT09774994 T AT 09774994T AT E516503 T1 ATE516503 T1 AT E516503T1
Authority
AT
Austria
Prior art keywords
head
selection
treatment
cancer patients
neck cancer
Prior art date
Application number
AT09774994T
Other languages
English (en)
Inventor
Heinrich Roeder
Maxim Tsypin
Julia Grigorieva
Original Assignee
Biodesix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biodesix Inc filed Critical Biodesix Inc
Application granted granted Critical
Publication of ATE516503T1 publication Critical patent/ATE516503T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/70—Machine learning, data mining or chemometrics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Theoretical Computer Science (AREA)
  • Biophysics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Computing Systems (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Software Systems (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Computation (AREA)
  • Databases & Information Systems (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Artificial Intelligence (AREA)
  • Data Mining & Analysis (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
AT09774994T 2009-01-20 2009-11-20 Auswahl von kopf-hals-krebspatienten für eine behandlung mit arzneimitteln zur anzielung des egfr-pfades ATE516503T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/321,393 US7867775B2 (en) 2006-03-31 2009-01-20 Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway
PCT/US2009/006269 WO2010085235A1 (en) 2009-01-20 2009-11-20 Selection of head and neck cancer patients for treatment with drugs targeting egfr pathway

Publications (1)

Publication Number Publication Date
ATE516503T1 true ATE516503T1 (de) 2011-07-15

Family

ID=41559566

Family Applications (1)

Application Number Title Priority Date Filing Date
AT09774994T ATE516503T1 (de) 2009-01-20 2009-11-20 Auswahl von kopf-hals-krebspatienten für eine behandlung mit arzneimitteln zur anzielung des egfr-pfades

Country Status (11)

Country Link
US (1) US7867775B2 (de)
EP (1) EP2247954B1 (de)
JP (1) JP5025802B2 (de)
KR (1) KR101131309B1 (de)
AT (1) ATE516503T1 (de)
AU (1) AU2009338174B2 (de)
CA (1) CA2718113A1 (de)
ES (1) ES2368784T3 (de)
IL (1) IL211943A (de)
TW (1) TWI368737B (de)
WO (1) WO2010085235A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906342B2 (en) * 2006-03-31 2011-03-15 Biodesix, Inc. Monitoring treatment of cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples
US7736905B2 (en) 2006-03-31 2010-06-15 Biodesix, Inc. Method and system for determining whether a drug will be effective on a patient with a disease
US7867775B2 (en) * 2006-03-31 2011-01-11 Biodesix, Inc. Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway
EP2539704A4 (de) * 2010-02-24 2015-12-02 Biodesix Inc Krebspatientenauswahl zur verabreichung von therapeutischen wirkstoffen unter verwendung von massenspektralanalyse
EP2668504A4 (de) 2011-01-28 2015-06-10 Biodesix Inc Vorhersagetest zur auswahl von metastatischen brustkrebspatienten für eine hormonelle kombinationstherapie
EP2864792A1 (de) 2012-06-26 2015-04-29 Biodesix, Inc. Massenspektrumsverfahren zur auswahl und zum ausschluss von krebspatienten für eine behandlung mit immunantworterzeugenden therapien
US8718996B2 (en) 2012-07-05 2014-05-06 Biodesix, Inc. Method for predicting whether a cancer patient will not benefit from platinum-based chemotherapy agents
US10037874B2 (en) 2014-12-03 2018-07-31 Biodesix, Inc. Early detection of hepatocellular carcinoma in high risk populations using MALDI-TOF mass spectrometry
CN112710723B (zh) 2015-07-13 2024-11-12 佰欧迪塞克斯公司 受益于pd-1抗体药物的肺癌患者的预测性测试和分类器开发方法
WO2017136139A1 (en) 2016-02-01 2017-08-10 Biodesix, Inc. Predictive test for melanoma patient benefit from interleukin-2 (il2) therapy
WO2017176423A1 (en) 2016-04-08 2017-10-12 Biodesix, Inc. Classifier generation methods and predictive test for ovarian cancer patient prognosis under platinum chemotherapy
EP3566054A4 (de) 2017-01-05 2020-12-09 Biodesix, Inc. Verfahren zur identifizierung von krebspatienten mit dauerhaften nutzen einer immuntherapie in untergruppen mit allgemein schlechter prognose
WO2019032525A1 (en) 2017-08-07 2019-02-14 Genecentric Therapeutics, Inc. PROCESS FOR SUBTYPING EPIDERMOID CARCINOMA OF HEAD AND NECK
WO2019046585A1 (en) * 2017-08-30 2019-03-07 Genecentric Therapeutics, Inc. ANALYSIS OF GENE EXPRESSION SUB-TYPES OF EPIDERMOID CARCINOMA OF HEAD AND NECK FOR TREATMENT MANAGEMENT
EP3773691A4 (de) 2018-03-29 2022-06-15 Biodesix, Inc. Vorrichtung und verfahren zur identifizierung der primären immunresistenz bei krebspatienten
CN116685259A (zh) * 2020-10-19 2023-09-01 本-古里安大学B.G.内盖夫技术和应用公司 尿细菌对抗生素的敏感性的快速直接鉴定和确定

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1540010B8 (de) 2002-08-06 2010-07-14 The Johns Hopkins University Verwendung von biomarkern zum nachweis von eierstockkrebs
CA2527321A1 (en) 2003-05-30 2004-12-23 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
US20050267689A1 (en) 2003-07-07 2005-12-01 Maxim Tsypin Method to automatically identify peak and monoisotopic peaks in mass spectral data for biomolecular applications
US20050048547A1 (en) 2003-07-17 2005-03-03 Hongyu Zhao Classification of disease states using mass spectrometry data
AU2005231101A1 (en) 2004-03-30 2005-10-20 Eastern Virginia Medical School Lung cancer biomarkers
EP2439285B1 (de) * 2004-03-31 2019-05-08 The General Hospital Corporation Verfahren zur Bestimmung des Ansprechens von Krebs auf den epidermalen Wachstumsfaktorrezeptor gerichtete Behandlungen
US20060029574A1 (en) 2004-08-06 2006-02-09 Board Of Regents, The University Of Texas System Biomarkers for diagnosis, prognosis, monitoring, and treatment decisions for drug resistance and sensitivity
US7908091B2 (en) 2006-03-17 2011-03-15 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
US7867775B2 (en) 2006-03-31 2011-01-11 Biodesix, Inc. Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway
US7736905B2 (en) * 2006-03-31 2010-06-15 Biodesix, Inc. Method and system for determining whether a drug will be effective on a patient with a disease

Also Published As

Publication number Publication date
ES2368784T3 (es) 2011-11-22
JP2011513728A (ja) 2011-04-28
IL211943A (en) 2014-01-30
US7867775B2 (en) 2011-01-11
AU2009338174B2 (en) 2012-02-02
KR101131309B1 (ko) 2012-04-02
TWI368737B (en) 2012-07-21
EP2247954B1 (de) 2011-07-13
JP5025802B2 (ja) 2012-09-12
IL211943A0 (en) 2011-06-30
WO2010085235A1 (en) 2010-07-29
TW201028688A (en) 2010-08-01
US20090171872A1 (en) 2009-07-02
EP2247954A1 (de) 2010-11-10
AU2009338174A1 (en) 2010-07-29
CA2718113A1 (en) 2010-07-29
HK1148073A1 (en) 2011-08-26
KR20110047171A (ko) 2011-05-06

Similar Documents

Publication Publication Date Title
ATE516503T1 (de) Auswahl von kopf-hals-krebspatienten für eine behandlung mit arzneimitteln zur anzielung des egfr-pfades
Ajani et al. ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients
Turnbull et al. Molecular basis of USP7 inhibition by selective small-molecule inhibitors
Nagel et al. Treatment response of HPV-positive and HPV-negative head and neck squamous cell carcinoma cell lines
Ko et al. Radiation therapy to enhance tumor immunotherapy: a novel application for an established modality
Brand et al. AXL is a logical molecular target in head and neck squamous cell carcinoma
Hersh et al. Molecular pathways and genomic landscape of glioblastoma stem cells: opportunities for targeted therapy
Yan et al. Up-regulation of syncytin-1 contributes to TNF-α-enhanced fusion between OSCC and HUVECs partly via Wnt/β-catenin-dependent pathway
Mittal et al. Recent advances in targeted therapy for glioblastoma
CR9390A (es) Mutaciones del receptor del factor de crecimiento epidermico
UA116665C2 (uk) Гібридний білок, що містить область фактора диференціації та росту 15 (gdf-15)
Sanchez et al. Targeted therapies for the neurofibromatoses
NZ710636A (en) Heterocyclic compounds and uses thereof
Jacobi et al. ErbB family signalling: a paradigm for oncogene addiction and personalized oncology
JP2011513728A5 (de)
Yu et al. Cbl-b regulates the sensitivity of cetuximab through ubiquitin-proteasome system in human gastric cancer cells
MX2010012408A (es) Metodos para predecir la respuesta de un paciente a los inhibidores del egfr.
Lamtha et al. Cannabinoids as Promising Inhibitors of HER2-Tyrosine Kinase: A Novel Strategy for Targeting HER2-Positive Ovarian Cancer
Muallaoglu et al. Lack of prognostic significance of C-erbB-2 expression in low-and high-grade astrocytomas
CN102994640A (zh) 一种检测 VEGFR2 mRNA 基因表达量的试剂盒及方法
Kara et al. A general aspect on soft-tissue sarcoma and c-kit expression in primitive neuroectodermal tumor and Ewing's sarcoma. Is there any role in disease process?
Bartık et al. Differential Effects of Sertraline and Penfluridol on EMT and ECM Remodeling in Glioblastoma Cell Lines
Sun et al. Treatment of inhibitors of tumor necrosis factor-a in endometriosis: Experimental study in vivo and in vitro
SHUANGRU DYNAMICS AND ORGANIZATION OF THE EPIDERMAL GROWTH FACTOR RECEPTOR INVESTIGATED BY IMAGING FLUORESCENCE CORRELATION SPECTROSCOPY
Shen et al. NT113, a potent and selective pan-ErbB inhibitor, is efficacious in vivo and has high brain penetrance.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties